Systematic review of fondaparinux for heparin‐induced thrombocytopenia: When there are no randomized controlled trials

BACKGROUND: Fondaparinux is commonly used for treatment of heparin-induced thrombocytopenia (HIT) despite lack of approval for this indication. High quality randomized controlled trials of this agent are unlikely to be forthcoming. OBJECTIVES: The objective of this systematic review is to update the literature on the efficacy and safety of fondaparinux for treatment of confirmed and probable HIT based on the available evidence.